bavituximab

Bavituximab is an investigational monoclonal antibody that blocks phosphatidylserine (PS) activation of multiple immune cell receptors, including TIMs and TAMs. PS is a phospholipid exposed on the surface of stressed cells in the tumor and its stroma. PS binding induces immunological non-responsiveness and reduces the ability of immune cells to recognize and fight tumors. Oncologie is focused on investigating the combination of this agent with other checkpoint inhibitors.

bavituximab

Bavituximab is an investigational immune-modulatory monoclonal antibody that blocks activation of tam and tim families of receptors on leukocytes by phosphatidylserine (PS). PS is a phospholipid exposed on the surface of stressed tumor cells and tumor blood vessels. PS binding induces immunological non-responsiveness and reduces the ability of immune cells to recognize and fight tumors.

on-going trials

Bavituximab With Radiation and Temozolomide for

Patients With Newly Diagnosed Glioblastoma

Link

Study of Pembrolizumab and Bavituximab in

Patients With Advanced Hepatocellular Carcinoma

Link

on-going trials

Bavituximab With Radiation and Temozolomide for Patients With Newly Diagnosed Glioblastoma

Study of Pembrolizumab and Bavituximab in Patients With Advanced Hepatocellular Carcinoma

 

This website uses cookies. By continuing to use this website you are giving consent to cookies being used.